牛牛AI助理已提取核心訊息
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
Janus Henderson Group plc, an investment firm based in Jersey, Channel Islands, has filed an amended Schedule 13G/A with the United States Securities and Exchange Commission on February 12, 2024, indicating that they now own less than 5% of Altimmune, Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reflects a change in ownership status as Janus Henderson's managed portfolios no longer hold a significant stake in Altimmune's common stock. The shares were held by Janus Henderson's subsidiaries, including Janus Henderson Investors U.S. LLC, Janus Henderson Investors UK Limited, and Janus Henderson Investors Australia Institutional Funds Management Limited, which are collectively referred to as the Asset Managers. The Asset Managers are registered investment advisers that provide investment advice to various funds and clients. The filing emphasizes that the shares were acquired in the ordinary course of business and not with the intention of changing or influencing the control of Altimmune.
總部位於海峽群島澤西島的投資公司Janus Henderson Group plc已於2024年2月12日向美國證券交易委員會提交了經修訂的附表13G/A，表示他們現在擁有生物製藥公司Altimmune, Inc. 不到5％的股份。該文件日期爲2023年12月31日，反映了所有權狀況的變化，因爲駿利亨德森的管理投資組合不再持有Altimmune普通股的大量股份。這些股票由駿利亨德森的子公司持有，包括駿利亨德森投資美國有限責任公司、駿利亨德森投資英國有限公司和駿利亨德森投資澳大利亞機構基金管理有限公司，這些子公司統稱爲資產管理公司。資產管理公司是註冊投資顧問，爲各種基金和客戶提供投資建議。該文件強調，這些股份是在正常業務過程中收購的，並不是爲了改變或影響Altimmune的控制權。
總部位於海峽群島澤西島的投資公司Janus Henderson Group plc已於2024年2月12日向美國證券交易委員會提交了經修訂的附表13G/A，表示他們現在擁有生物製藥公司Altimmune, Inc. 不到5％的股份。該文件日期爲2023年12月31日，反映了所有權狀況的變化，因爲駿利亨德森的管理投資組合不再持有Altimmune普通股的大量股份。這些股票由駿利亨德森的子公司持有，包括駿利亨德森投資美國有限責任公司、駿利亨德森投資英國有限公司和駿利亨德森投資澳大利亞機構基金管理有限公司，這些子公司統稱爲資產管理公司。資產管理公司是註冊投資顧問，爲各種基金和客戶提供投資建議。該文件強調，這些股份是在正常業務過程中收購的，並不是爲了改變或影響Altimmune的控制權。
有用
沒用